Navigating troubled waters: a systematic review of prosthetic valve endocarditis reported cases treated with suppressive antimicrobial treatment
Pietro Valsecchi, Matteo Calia, Paola Giordani and 5 more
International Journal of Infectious Diseases · 2025
doi:10.1016/j.ijid.2025.107934 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Objectives: We aimed to characterize suppressive antimicrobial treatment (SAT) for non-surgical candidate patients with prosthetic valve endocarditis (PVE). Methods: We systematically reviewed PubMed and Embase databases for studies reporting individual data on patients with PVE medically treated for longer than 8 weeks published until the 31st of June 2024. The review protocol was registered on PROSPERO database [CRD42024529650]. Results: One hundred seventy patients were retrieved from 91 studies. PVE-related death during follow-up occurred in 26 (15.57%) patients, being associated with coagulase-negative staphylococci PVE in multivariate Cox regression model (HR 3.40, 95% CI 1.06-10.97, P-value = 0.04). Relapse occurred in 15 (8.92%) patients and was similar according to SAT discontinuation (long-rank test P-value = 0.8). This was confirmed after performing landmark analysis to adjust for survival bias (HR 0.97; 95% CI 0.21-4.4, P-value = 0.98). SAT-related adverse events were reported in 15% of the patients. Conclusion: Supporting evidence for SAT is low and derived from case reports and case series. SAT seems well tolerated, but clinical effectiveness should be further evaluated due to the relevant mortality rate. In selected cases when SAT discontinuation is considered, close and long-term follow-up is crucial to prevent relapse.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.